[Prevalence and clinical course in HBV and HCV dual chronic infection].
Tamori
Akihiro
A
Department of Hepatology, Osaka City University Graduate School of Medicine.
Nishiguchi
Shuhei
S
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use; D015897:Comorbidity; D004359:Drug Therapy, Combination; D019694:Hepatitis B, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology*; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D015995:Prevalence; D012254:Ribavirin / Q000627:therapeutic use; D015163:Superinfection
D000998:Antiviral Agents; D019259:Lamivudine; D012254:Ribavirin; D007372:Interferons